{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:11:04Z","timestamp":1779923464723,"version":"3.53.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Direct"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Direct-acing antiviral agents are highly efficient treatment options for chronic hepatitis C virus (HCV) infection after renal allograft transplantation. Treatment options for patients with impaired graft function remain limited. Therefore, we assessed the effectiveness and safety of grazoprevir\/elbasvir therapy for patients with chronic HCV infection and impaired renal allograft function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Eleven renal allograft recipients with therapy-na\u00efve HCV genotype (GT) 1a, 1b, or 4 were treated with the fixed-dose combination of elbasvir\/grazoprevir without ribavirin for 12 weeks. All recipients exhibited impaired graft function with an average glomerular filtration rate lower than 30 mL\/min per 1.73 m<jats:sup>2<\/jats:sup>. Clinical data were retrospectively reviewed for renal and liver function parameters. Patients were closely monitored for trough levels of immunosuppressive agents, viral load, laboratory values, and potential adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Seven (64%) patients exhibited a rapid virologic response within 4 weeks (HCV GT1a, n = 2; HCV GT1b, n = 5). The other 4 patients exhibited a virologic response within 8 weeks (HCV GT1b, n = 3; HCV GT 4, n = 1). All patients exhibited a sustained virologic response at week 12 after the end of treatment. Clinical measures of liver function improved substantially for all patients. Few adverse effects were reported. Impaired renal allograft function and proteinuria remained stable. For most patients, only moderate adjustments to the tacrolimus dosage were necessary for maintaining sufficient trough levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This treatment appears to be safe and effective for renal transplant recipients with impaired allograft function and is a promising treatment option for eradicating HCV infection in this patient population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000000860","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T01:14:14Z","timestamp":1546564454000},"page":"e419","source":"Crossref","is-referenced-by-count":6,"title":["Treatment With Grazoprevir\/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function"],"prefix":"10.1097","volume":"5","author":[{"given":"Ute","family":"Eisenberger","sequence":"first","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justa","family":"Friebus-Kardash","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Guberina","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Willuweit","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Gerken","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Herzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,1]]},"reference":[{"key":"bib1-20231002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hep.24470","article-title":"Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents\u2014a potentially lethal cocktail","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.4254\/wjh.v7.i9.1287","article-title":"Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant","volume":"7","year":"2015","journal-title":"World J Hepatol"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jhep.2017.03.006","article-title":"ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"bib5-20231002","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1097\/TP.0000000000001758","article-title":"Elbasvir\/grazoprevir use in postliver transplantation patients on hemodialysis","volume":"101","year":"2017","journal-title":"Transplantation"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"key":"bib7-20231002","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"bib8-20231002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bcp.13095","article-title":"Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C","volume":"83","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/TP.0000000000001414","article-title":"Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients","volume":"101","year":"2017","journal-title":"Transplantation"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jceh.2017.01.116","article-title":"Potential liver transplant recipients with hepatitis C: should they be treated before or after transplantation?","volume":"7","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"bib13-20231002","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1756283X16671293","article-title":"Grazoprevir\/elbasvir combination therapy for HCV infection","volume":"10","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"bib14-20231002","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"29","year":"1999","journal-title":"Hepatology"},{"key":"bib15-20231002","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/01.TP.0000131948.29742.24","article-title":"Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation","volume":"78","year":"2004","journal-title":"Transplantation"},{"key":"bib16-20231002","first-page":"159760","article-title":"Hepatitis C virus infection and dialysis: 2012 update","volume":"2013","year":"2012","journal-title":"ISRN Nephrol"},{"key":"bib17-20231002","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2215\/CJN.02930806","article-title":"The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment","volume":"2","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"bib18-20231002","first-page":"16","article-title":"Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation","volume":"75","year":"2011","journal-title":"Clin Nephrol"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","article-title":"Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?","volume":"19","year":"2012","journal-title":"J Viral Hepat"},{"key":"bib20-20231002","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ki.1995.78","article-title":"Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis","volume":"47","year":"1995","journal-title":"Kidney Int"},{"key":"bib21-20231002","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","year":"2012","journal-title":"J Infect Dis"},{"key":"bib22-20231002","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.tp.0000238898.14393.c9","article-title":"Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant","volume":"82","year":"2006","journal-title":"Transplantation"},{"key":"bib23-20231002","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e318273fec4","article-title":"Hepatitis C virus and nonliver solid organ transplantation","volume":"95","year":"2013","journal-title":"Transplantation"},{"key":"bib24-20231002","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"bib25-20231002","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jhep.2012.02.020","article-title":"Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"bib26-20231002","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"bib27-20231002","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ckj\/sfx067","article-title":"Do we really need more evidence to use hepatitis C positive donor kidney more liberally?","volume":"10","year":"2017","journal-title":"Clin Kidney J"},{"key":"bib28-20231002","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to non-infected recipients: an open-label nonrandomized trial","volume":"168","year":"2018","journal-title":"Ann Intern Med"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01845228-201901000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:26:19Z","timestamp":1696231579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01845228-201901000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000000860","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}